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Abstract
Background: The incidence of malignant melanoma (MM) was occurring at a faster rate than for most neoplasm
worldwide, and melanoma metastasis is still the most formidable problem. So it is necessarily to find some
biomarkers associated with melanoma metastasis.
Methods: In our study, 8 spontaneous lung metastatic mice models were created by B16F10 subcutaneously
transplantation. The differential protein profiles of two kinds of subcutaneous transplanted tumor tissues, which
was parental B16F10 (B16 group) and corresponding lung metastases (B16M group) were detected by two-
dimensional differential in-gel electrophoresis (2D-DIGE) combined with matrix-assisted laser desorption/ionization
time-of-flight mass spectrometry (MALDI-TOF/MS). Western blotting was used to validate the results, and the
clinical significance of individual protein was detected furtherly in a set of human samples.
Result: In this study, thirty proteins were found to be differentially expressed (ratio > 2 or < -2, P < 0.01) and
thirteen of them were identified by MS. Highly expressed proteins in B16M group included cytoskeleton/structure
proteins (vimentin, gamma-actin, b-actin, laminin binding protein), the chaperone family of proteins (heavy-chain
binding protein, Bip), immunoproteasome assembly (proteasome activator REG alpha) and others involved in
glycolysis activity (PGK1, enolase, TPI, human skeletal muscle GAPDH) and protein transport (myoglobin). Vimentin
was significantly up-regulated in B16M group compared with B16 group which was validated by western blotting.
Immunohistochemistry was performed in a set of clinical samples, the results showed that over-expression of
vimentin was frequently observed in primary melanoma patients with hematogenous metastasis (P < 0.05), not
associated with lymph node metastasis (P > 0.05). The presence of TNM stage was a independent indicator of poor
prognosis for melanoma patients (P = 0.004).
Conclusion: The aberrant immunohistochemical expression of vimentin in primary melanoma tissues may help to
call attention for patients with high risk of hematogenous metastasis. That might be as a novel metastatic indicator
for melanoma. In a word, vimentin is not only the dignostic marker but also the hematogenous metastasis
predictor for melanomas clinically.
Background
The numbers of malignant melanoma (MM) cases
worldwide are increasing faster than any other cancers.
It is estimated that the 68,720 new cases of MM will be
diagnosed in the United States in 2009 according to
SEER Stat Fact Sheets from NCI report [1]. MM is char-
acterized by its intensive metastatsis, therapy-resistant
and high mortality. One person dies per hour from
metastatic melanoma [2]. Hence tremendous research
efforts have been thrown into seeking some biomarkers
of metastasis-forecasting for melanoma. Some studies of
using high-throughout gene microarray have revealed
several putative genes associated with melanoma metas-
tasis, such as SPP-1, MITF, CITED-1, GDF-15, c-Met
and so on [3], but none of them was tested the signa-
ture in clinical materials.
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Genome Database, i.e. proteomics has been generally
utilized to identify protein biomarkers associated with
tumor development and progression. 2D-DIGE (two-
dimensional differential in-gel electrophoresis) has
higher resolution compared with traditional 2-DE (two-
dimensional polyacrylamide gel electrophoresis), which
is an advanced quantitative proteomics technology that
is of great sensitivity and accuracy [4]. It is a method of
prelabeling fluorescent cyanine dyes (Cy2, Cy3, Cy5) to
different samples prior to 2-DE. Therefore, different
samples can be labeled with the different dyes and sepa-
rated in the same 2D gel. This technique enables the
same internal standard in every gel so as to overcoming
the intergel variation. Thus accurate quantitation of dif-
ferences between samples could be accomplished by 2D-
DIGE with high reproducibility and reliability [4].
B16 was derived from a spontaneous melanoma in a
C57BL/6J mouse. The subline of B16-F10 was arised
from the lung metastasis of the parent B16 line in vivo
after i.v. injection and subsequently cultured in vitro
after 10 cycles of lung colony formation [5]. Usually,
there are two ways to establish lung metastasis, i.e.
spontaneous metastasis by inoculation of tumor cells
subcutaneously and experimental metastasis by injection
of tumor cells directly into the bloodstream. The former
one may be better to reflect the metastatic process of
the human being than latter. Therefore, using the sub-
cutaneous transplanted tumor tissues from parental
B16-F10 (B16 group) and corresponding lung metastases
(B16M group) as proteomic objectives may be the most
directly and persuasively way to discover metastatic bio-
markers for melanoma.
The aim of this study was to investigate novel pro-
teins involving in the metastasis of melanoma by using
2D-DIGE analysis followed by MALDI-TOF/TOF-MS.
Furthermore, we examined the properties of these
proteins to be metastatic biomarker candidates. The
significant protein was successfully validated by immu-
nohistochemistry in 70 primary melanoma cases. This
is the first report to confirm the proteomic results in
the bulk of clinical specimens.
Materials and methods
Cells and animals
Mouse melanoma B16-F10 cells were offered by Tianjin
Cancer Hospital. The procedure of engrafted melanoma
cells was performed as same as Sun described previously
[6]. Till the commence of our study, eight spontaneous
metastatic models (B16M group) have been created, and
the lungs with metastases have been inoculated into the
mice groin to be passaged subsequently. The individual
passage times were different from 18 to 33 until the
experimental tissues collection.
All six- to eight-week old C57BL/6J mice were pur-
chased from the Animal Center Academy of Military
Medical Science. Eight mice were inoculated with B16-
F10 suspensions subcutaneously as control group (B16
group). Fifteen days after inoculation, the mice were
sacrificed after tumors were harvested. The tumor sam-
ples were quickly frozen in liquid nitrogen and kept at
-80°C for further analysis.
Sample preparation and Cy-dye labeling
The frozen tumor samples from two groups were
grinded into fine powder in liquid nitrogen and homo-
genized in lysis buffer (7M urea, 2M thiourea, 4%
CHAPS, 10 mM of Tris, 5 mM of magnesium acetate, a
complete proteinase inhibitor cocktail tablet per 50 mL
lysis buffer), and then solubilized by sonicator (Microson
TM Ultrasonic Cell Disruptor, USA) on ice for 1 min.
The samples were incubated for 30 min at room
temperature with repeated vortexing. They were then
centrifuged at 12 000 × g for 40 min at 20°C. The
supernatants were saved and total protein concentration
was determined with the Bradford assay kit (BioRad).
Fifty ug of individual sample lysates were labeled with
Cy3 or Cy5 (200 pmol), and equal quantities samples
mixed was labeled with Cy2 as the internal pool stan-
dard on all gels to aid protein-spot matching cross-gel.
Samples were reverse-labeled in order to eliminate
either sample-dependent or dye-dependent bias. The
labeling process was carried out in the dark on ice for
30 min, and terminated with 1 ul of 10 mM lysine for
10 min on ice. These differently-labeled protein samples
were then mixed for 2D-DIGE analysis.
2D-DIGE
2D-DIGE was performed as same as Zhang described
earlier [7]. Briefly the proteins were applied to IPG
strips (pH 3-10, NL, 24 cm) and first-dimension isoelec-
tric focusing (IEF) was performed using an Ettan IPG-
phor System (GE Healthcare). The strips which were
treated with reduction and alkylation steps were over-
layered onto 12% SDS polyacrylamide gels (20 × 24 cm)
for second dimensional protein separation by using an
Ettan DALT Twelve System (GE Healthcare). After
SDS-PAGE, the Cy2, Cy3, and Cy5-labeled images were
scanned by a laser scanner (Typhoon 9410, GE Health-
care) in fluorescence mode at appropriate excitation/
emission wavelengths of 488/520, 532/580, and 633/670
nm respectively.
Image analysis
The images were analyzed by using DeCyder Differential
Analysis Software v6.0 (Amersham GE Healthcare) to
detect, quantify and normalize the protein spots intensi-
ties in each gel. Differential in-gel analysis (DIA) module
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Cy5 for each gel, while biological variation analysis
(BVA) module was used to automatic match all protein-
spot maps. The Cy3/Cy2 and Cy5/Cy2 DIA ratios were
used to calculate average abundance changes and paired
Student’s t-test was conducted. The differential protein
spots (ratio > 2 or < -2, P < 0.01) which were statisti-
cally significant were selected for furthrt identification.
Spot digestion and MALDI-TOF analysis
Picking the spots, in-gel digestion and MS protein analy-
sis were described as Zhang [7]. Briefly, separate pre-
parative gels which were fixed in 30% v/v methanol,
7.5% v/v acetic acid and stained with colloidal Coomas-
sie Brilliant Blue were used to acquire enough amounts
of proteins. Excision of selected protein spots which
were interested and confirmed by the 2D-DIGE/DeCy-
der analysis was subsequently performed with an Ettan
Spot Picker. The protein containing gel pieces were dis-
colored with 50% ACN and 25 mM of ammonium
bicarbonate, then reduced and alkylated in 10 mM of
DTT and 55 mM of iodoacetic acid gradually. The
samples were dried by a vacuum centrifuge and were
thoroughly incubated with the digestion buffer (linear-
gradient Trypsin, a final concentration of 0.01 mg/mL
in 25 mM of ammonium bicarbonate) for 16 h at 37°C.
After digestion, the samples were centrifuged and the
supernatants were removed, vacuum-dried and redis-
solved in 50% ACN and 0.1% TFA until analysed by MS.
Mixtures of tryptic peptides were eluted onto the 192-
well MALDI sample plates with equal amounts of the
matrix solution (7 mg/mL CHCA in 0.1% TFA, 50%
ACN). Samples were then analyzed by an ABI 4700 Pro-
teomics Analyzer MALDI-TOF/TOF mass spectrometer
(Applied Biosystems, USA) to get the peptide mass finger-
print (PMF). Cysteine carbamidomethylation and methio-
nine oxidation were considered as variable modifications.
A maximum number of one missed cleavage per peptide
was allowed. Precursor error tolerance was set to < 0.1 Da
and MS/MS fragment error tolerance < 0.2 Da. When a
single spot represented diverse proteins, the proteins com-
posed of highest number of peptides were regarded as cor-
responding ones. MASCOT search engine (Matrix
Science, London, U.K.) was employed to match peptide
and search protein against the NCBInr database. Proteins
with score value over 60 were positively identified.
Western blotting
Protein samples were separated by 10% SDS-PAGE gels
and then transferred to PVDF membranes. After
blocked with 5% defatting milk for 1 h at 37°C, the
membranes were incubated with anti-vimentin (1:1000,
Thermo Scientific, USA) at 4°C overnight. After washing
with 0.5% PBS-T (PBS with Tween-20) for three times,
the membranes were incubated with a horseradish per-
oxidase-conjugated secondary antibody for 1 h at 37°C.
Membranes were washed again with PBS-T. The signals
were detected by using the Western blotting chemilumi-
nescent kit (Pierce), quantified by densitometry and ana-
lyzed by using Quantity One image analysis system
(BioRad). The detection of b-actin (1:5000, Santa Cruz,
USA) was used as the inner control.
Patients
Paraffin-embedded melanoma specimens (n = 70) were
obtained from the Tianjin Cancer Hospital from 1998 to
2003. Detailed pathological and clinical data were col-
lected and none of the patients had received treatment
before operation. Clinical outcome was followed from
the date of surgery to the date of death or until Jan,
2009. The summary of the clinicopathological data of
the cases is shown in Table 1. Of 70 enrolled cases, 43
males and 27 females (mean age, 54.96 ± 12.60 years).
The sites of melanomas were trunk (13/70), limbs (27/
70), head and neck (13/70), digestive system (8/70) and
genital system (9/70) respectively. We categorized them
into two groups: cutaneous melanoma (53/70) and
extra-cutaneous melanoma (17/70). The survival dura-
tions ranged from 1 to 113 months (mean, 34.90 ±
27.42 months). Primary melanoma with hematogenous
metastasis was observed in 29 cases. This study was
approved by the ethics committee.
Immunohistochemical staining of patients samples
Seventy formalin-fixed, paraffin-embedded melanoma
patients samples were cut into 4 μm sections and dried
overnight at 65°C. The sections were deparaffinized in
xylene and rehydrated through graded alcohols into
water. Endogenous peroxidase was blocked with 3%
hydrogen peroxid for 20 min in the dark chamber.
Microwave antigen retrieval was performed using citrate
buffer (0.01 M citric acid, pH 6.0) for 20 min at 100°C
in a microwave oven. After rinsing with PBS, the slides
were incubated with anti-vimentin (1:100, Thermo
Scientific, USA) overnight at 4°C. Visualization was per-
formed using the diaminobenzidine (Zhongshan, Beijin,
China) according to the manufacturer’s instructions.
Appropriate positive and negative controls were estab-
lished. The sections were counterstained with hematoxy-
lin in the end.
The positive expression of vimentin was yellow stain
in the cytoplasm of melanoma cells. Ten “hot spots”
under high-power fields were selected randomly, and
100 cells per field were counted. The average percentage
of positively stained cells of 10 fields was converted into
a score as follows: 0 for < 20%, 1 for < 40%, 2 for <
60%, and 3 for > 60%. A score between 2 and 3 was
considered to be strong expression.
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The statistical analysis was conducted using SPSS ver-
sion 13.0 (SPSS, Chicago, IL, USA). P-value less than
0.05 was defined as significant level. Values are shown
as mean ± SD or percentages. The c
2 test, the Student’s
t-test and the Mann-Whitney test were used in our
study. Kaplan-Meier survival analysis and log-rank test
were performed to compare the survival time between
each group. Multivariate survival analysis was performed
using the Cox proportional hazards model.
Results
2D-DIGE Images of Proteins
Protein profiles which were potentially involved in
metastasis were analyzed by 2D-DIGE which was
repeated independently for three times under identical
condition. The threshold of proteins differential
expression was set at great than 2-fold, and the P
value of < 0.01 of t-test was regarded as statistical sig-
nificance. Thirty spots across all images were differen-
tial significantly. They were subsequently excised,
subjected to trypsin digestion in-gel and analyzed by
MALDI-TOF/TOF- MS. Thirteen proteins of them
were successfully identified by PMF analysis and pep-
tide sequences analysis in the NCBInr database (Table
2). Of the 13 protein spots, 11 were higher abundance
and 2 were at lower levels in the metastatic group.
Highly expressed proteins in B16M group included
cytoskeleton/structure proteins (vimentin, gamma-
actin, b-actin, laminin binding protein), the chaperone
family of proteins (heavy-chain binding protein, Bip),
immunoproteasome assembly (proteasome activator
REG alpha) and others involved in glycolysis activity
(PGK1, enolase, TPI, human skeletal muscle GAPDH)
and protein transport (myoglobin). MALDI-TOF/TOF-
MS analysis and database matching identified spot 625
was vimentin with high sequence coverage and mass
accuracy (Figure 1A-C).
Validation of vimentin expression by western blotting
Western blotting was performed to verify the differential
expression of vimentin in eight pairs of B16M group
and B16 group. Equal expression of b-actin as internal
standard was to identify the same protein loading. As
s h o w ni nF i g u r e1 D - E ,v i m e n t i nw a ss i g n i f i c a n t l yu p -
r e g u l a t e di nB 1 6 Mg r o u pc o m p a r e dt oB 1 6g r o u p( P<
0.05), which was consistent with the 2D-DIGE results.
Expression of vimentin in melanoma patients
We further detected the expression of vimentin using
immunohistochemistry in 70 primary malignant mela-
noma patients to evaluate its clinicopathological signifi-
cance. The differential expression of vimentin was
shown in Figure 2A-B. Primary melanomas with overex-
pression of vimentin tends to have a more hematogen-
ous metastasis incidence (P <0 . 0 5 ) .T h e r ei sn o
statistical significance between overexpression of vimen-
tin with age, gender, tumor location, TNM stage and
lymph node metastasis (Table 1). Cox proportional
hazards model analysis was performed and showed that
the presence of TNM stage was a independent indicator
of poor prognosis for melanoma patients (P = 0.004).
Discussion
Melanoma metastasis is the most insidious and life-
threatening. To identify the metastasis-associated
biomarkers may help to provide risk assessments and
personal therapeutic strategies for melanoma patients.
The earlier detection such accurate biomarkers in the
primary tumors, the better prognosis and interventional
treatments would patients have. Along with the
advanced technologies, a series of high-throughput DNA
Table 1 Correlation of vimentin expression with clinicopathologic features of 70 primary melanoma patients
Patients Characteristics Factors n vimentin expression c
2 p value
(N = 70) low high
Age(y) < 60 43 21 22 0.128 0.808
≥60 27 12 15
Gender Male 43 15 12 1.248 0.328
Female 27 18 25
Location Cutaneous 45 22 23 0.154 0.804
Extra-cutaneous 25 11 14
TNM Stage I 16 10 6 2.145 0.342
II 24 11 13
III 30 12 18
Lymph node metastasis positive 28 12 16 0.344 0.629
negative 42 21 21
Hematogenous metastasis positive 29 8 21 7.599 0.008*
negative 41 25 16
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targets associated with metastatic biological phenotypes
of melanomas [8-10]. However, the proteome is the
functional translation of the genome and can regulate
cancer cells behavior directly. Neither the DNA
sequences nor the amount of RNA could predict post-
translational aberrations resulting from phosphorylation,
glycosylation or proteolysis[11]. So it is reasonable that
the proteomics should reflect the tumor characteristic
more directly than genomics.
Till now, there have been a number of researches
focusing on detecting the metastatic biomarkers for mel-
anoma by using the proteomics methodologies [12-14].
The cell lines of different biological features were used
as the compared objectives customarily and 2-DE com-
bined with MS were most favorable methods for proteo-
mics. The traditional 2-DE is short of reproducibility
owing to gel-to-gel variation. That has been resolved by
advanced technique of 2D-DIGE which is of higher sen-
sitivity and reproducibility. In 2D-DIGE, the protein
extracts are labeled with fluorescent cyanine dyes, mixed
and separated in the same 2D gel where has a unified
internal standard [4,15]. For its ascendancy, we applied
it instead of the classical 2-DE in this study.
I no r d e rt od i s c o v e rm e t a s t a sis-associated biomarks
for melanoma, the research objectives originating from
the primary tumors with those corresponding metastases
of the same patients are the optimum. Unfortunately, it
is too difficult to acquire such specimens clinically. For
this reason, we created the mice models bearing sponta-
neous lung metastasis by using B16-F10 subcutaneously
inoculation. That metastatic process could mimic the
procedure in the human body. The metastatic “black
spots” on the mouse lung were picked out, transplanted
into the mouse groin and then growed into transplanted
tumor which were passaged sequentially and stably. We
compared the differential protein profiles to identify
which proteins were varied during the metastatic
process.
In this study, thirty proteins were differential
expressed statistically between two groups and thirteen
of them were successfully identified by MS. Functional
analysis demonstrated that proteins of higher abundance
in metastatic process were more associated with cytos-
keletal structure, glycometabolism, protein folding, and
immune response, suggesting that these proteins should
be involved in melanoma progression. Several up-
regulated proteins, such as laminin binding protein and
GRP78 (Bip) have been reported that played important
roles in either melanoma progression or various cancers
metastasis [16-18]. Furthermore, another individual up-
regulated proteins in our study have already been identi-
fied as metastatic markers in other types of cancer by
using proteomics methods, these were PA28 (protea-
some activator alpha) implicated in ovary cancer [19],
a-enolase in hepatocellular carcinoma [20], triosepho-
sphate isomerase in lung squamous carcinoma [21] and
PGK1 in gastric cancer [22].
The most valuable significance of our study is to dis-
cover that vimentin might be served as a potential bio-
marker for predicting the melanoma hematogenous
metastasis by using one set of clinical samples. Vimentin
was up-regulated 2.06 folds in the B16M group com-
pared with the B16 group in 2D-DIGE and the result
Table 2 The list of differential proteins identified by MS
spot
no.
Acession
number
identified protein average
ratio
M.W
(Da)
PI Protein
coverage
Protein
score C.I.%
Functional
classification
520 gi|17389985 MB protein [Homo sapiens] myoglobin 2.13 10863 9.24 40% 100 Transport
597 gi|31873302 hypothetical protein [Homo sapiens] -3.24 47063 7.57 8% 99.993
625 gi|47115317 VIM [Homo sapiens] 2.06 53547 5.09 27% 97.337 Cytoskeleton
641 gi|16552261 unnamed protein product [Homo sapiens] -2.7 47459 5.01 42% 100
687 gi|178045 gamma-actin[Homo sapiens] 2.26 25862 5.65 14% 100 Cytoskeleton
719 gi|48145549 PGK1 [Homo sapiens] 3.08 44574 8.30 28% 100 Glycolytic Enzymes
756 gi|1125065 laminin-binding protein laminin receptor 3.05 14104 7.03 16% 98.157 Cytoskeletal/
structural protein
830 gi|230867 Chain R, Twinning In Crystals Of Human Skeletal
Muscle GAPDH
4.16 35853 6.60 11% 100 Glycolytic Enzymes
888 gi|15277503 ACTB protein [Homo sapiens] b-actin 3.09 40194 5.55 17% 100 Cytoskeleton
952 gi|2780871 Chain B, Proteasome Activator Reg(Alpha) 3.71 16285 7.14 14% 99.989 Immunoproteasome
assembly
976 gi|999892 Chain A, Crystal Structure Of Recombinant Human
Triosephosphate Isomerase
4.12 26522 6.51 22% 99.594 Glycolytic Enzymes
1153 gi|6470150 BiP protein [Homo sapiens] 3.12 70888 5.23 41% 100 the chaperone
family of protein
1158 gi|4503571 enolase 1 [Homo sapiens] 4.72 47139 7.01 41% 100 Glycolytic Enzymes
* average ratio, B16M group/B16 group
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Page 5 of 9Figure 1 The images of representive 2D-DIGE and validation of vimentin. (A) A representative 2D-DIGE gel images. The extracted proteins
were labeled with fluorescent dyes and separated by 2D-DIGE. B16M group was labled with cy3, B16 group was labled with cy5. (B) A
representative two-dimensional gel image. Differential expressed proteins that have been successfully identified by MALDI-TOF/MS (p ≤ 0.05,
protein fold≥2) are circled and numbered. The spot numbers correspond to those proteins listed in Table 1. (C) The magnified protein spot
images of vimentin in 2D gel showing the significant over-expression in B16M group compared with B16 group. (D) Western blotting shows
changes in expression levels of vimentin in B16M group and B16M group; b-actin is used as the internal loading control. (E) Histogram showing
the relative expression levels of vimentin in eight pairs of B16M and B16 tissues, as determined by densitometric analysis (p = 0.021).
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clinicopathological analysis was performed to detect
whether there had differential expression of vimentin in
primary tumors with or without hematogenous metasta-
sis by immunohistochemical staining. The data showed
that high expression of vimentin was significantly asso-
ciated with melanoma hematogenous metastasis. There
was more occurrence of over expression of vimentin in
primary melanomas with hematogenous metastasis (21/
29, 72. 41%) compared to non-hematogenous metastasis
(16/41, 39.02%). However, the expression of vimentin is
not differential significantly between primary melanomas
with lymph nodes metastasis (16/28, 57.14%) with non-
lymph nodes metastasis (21/42, 50%). So we presume
that vimentin should have special biological features in
melanoma hematogenous metastasis, not involving in
lymph node metastasis. Although cutaneous melanoma
is the majority type, extra-cutaneous melanoma is still
occupying a small part. Sixteen of the former (16/45)
and thirteen of the latter (13/25) were positively for
hematogenous metastasis. It seemed that extra-
cutaneous melanoma have more occurrence of hemato-
genous metastasis. The prognostic factors for cutaneous
melanoma include Breslow tumor thickness, Clark’s
level, ulceration and lymph node metastasis [23]. In our
study, for cutaneous melanoma and extra-cutaneous
melanoma, the TNM stage is an independent indicator
of poor prognosis.
Generally, vimentin is usually used as a marker to
diagnose human melanoma clinically. But with the
increasing knowledge about it, we have known that the
extensive function of vimentin are far more than these.
Numerous studies relating to proteomics have shown
that vimentin was metastasis-associated factor in multi-
ple malignancies, such as prostate cancer [24], breast
cancer [25], gastric cancer [26], and galbladder cancer
[27]. That suggests that vimentin should play an impor-
tant role in tumor progression and serve as a potential
biomarker for the metastasis. There still have some stu-
dies which were concerning of aberrant overexpression
of vimentin and its relationship with melanoma metasta-
sis [28,29]. On the whole, we first demonstrated the sig-
nificant upregulation of vimentin in metastatic
melanoma compared to primary cases by proteomics
and carried out the clinical verification to evalute
whether vimentin is a potential biomarker for predicting
the metastasis in melanoma patients.
Vimentin is one of the most familiar members of
intermediate filaments (IFs) which is the characteristic
of mesenchymal cells. IFs, actin microfilaments and
microtubules are three major structural components of
the cytoskeleton which are in charge of contraction and
migration of cells. In addition, the stucture where
vimentin, actin associate with integrins and where vin-
culin and plectin recruited were termed as the vimentin
associated matrix adhesions (VAMs) [30]. Of our results,
laminin receptor and actin (b,g) were all up-regulation
in the metastatic group. It revealed that cytoskeleton
proteins might be associated with melanoma metastasis
intensively. Metastasis is a complicated process, of them
adhesion is a prerequisite step by which tumor cells
could be easy to migrate, invade and detach from the
primary tumour. Recent studies have revealed that
vimentin has key roles in adhesion by regulating integrin
functions [31]. So it could be as a therapeutic target for
melanoma in the future. In addition to this, Vimentin is
still the predominant mesenchymal marker which is aty-
pical expressed in the epithelial-mesenchymal transition
(EMT). EMT is the process that the epithelial cells
acquire the mesenchymal phenotype with more
Figure 2 The immunohistochemical expression of vimentin in melanoma patients. (A) High expression of vimentin in primary melanoma
tissue with hematogenous metastasis. ×400 (B) Low expression of vimentin in primary melanoma tissue without hematogenous metastasis. ×400.
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more attentions have been focused on the EMT which
seems to act as a switch for the initial cancer metastasis
[32]. Generally, EMT is defined as the upregulation of
mesenchymal markers and downregulation of epithelial
markers. Till now, there have been some reports to
identify that melanoma metastasis were associated with
EMT [33,34]. Alonso et al [34] confirmed that the
expression of a set of proteins included in the EMT
group (N-cadherin, osteopontin, and SPARC/osteonec-
tin) were significantly associated with metastatic devel-
opment of melanomas using cDNA microarrays. In our
MS results, only vimentin and actin were identified up-
regulated, no other epithelial markers were identified,
that is one shortcoming of our study. So it is merely a
hypothesis that vimentin involving in the melanoma
metastasis is by EMT progression.
Conclusions
This is the first report to validate the proteomics results
in a set of melanoma samples. Our results showed that
increased expression of vimentin might be as a novel
metastatic indicator for melanoma. In other words,
vimentin is not only the dignostic marker but also the
hematogenous metastasis predictor for melanomas clini-
cally. The aberrant immunohistochemistry expression of
vimentin in primary melanoma tissues may help to call
attention for patients with high risk of hematogenous
metastasis. Accordingly, we could have possibility to
predict the clinical outcome, and then to provide indivi-
dual treatment strategies for melanoma patients.
Abbreviations List
BVA: biological variation analysis; DIA: differential in-gel analysis; EMT:
epithelial-mesenchymal transition; IEF: isoelectric focusing; IFs: intermediate
filaments; MM: malignant melanoma; PMF: peptide mass fingerprint; 2-DE:
two-dimensional polyacrylamide gel electrophoresis; 2D-DIGE: two-
dimensional difference gel electrophoresis; vimentin VAMs: associated matrix
adhesions
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
BGZ, ML and XW carried out experimental procedures and drafted
manuscript. TS, XCB and ZYL participated in its design and carried out the
molecular experiments. XLZ revised it critically. BCS guaranted the whole
study. All authors read and approved the final manuscript.
Acknowledgements
This work was supported by a grant from a Key project of the National
Natural Science Foundation of China(No.30830049), the National Natural
Science Foundation of China(No.30770828), and Tianjin Natural Science
Foundation(Nos.09ZCZDSF04400).
Author details
1Department of Pathology, The key lab of cancer prevention and treatment,
Tianjin Cancer Institute and Hospital, Tianjin Medical University, Tianjin
300060, P.R. China.
2Department of Pathology, Tianjin Medical University,
Tianjin 300070, P.R. China.
3Department of Digestive, The Second Hospital of
Tianjin Medical University, Tianjin 300211, P.R. China.
4Tianjin Children
Hospital, Tianjin 300074, P.R. China.
Received: 3 May 2010 Accepted: 11 August 2010
Published: 11 August 2010
References
1. American Cancer Society: Cancer Facts & Figures 2009. Atlanta: American
Cancer Society 2009.
2. Jemal A, Devesa SS, Harlge P: Recent trends in cutaneous melanoma
incidence among whites in the United States. J Natl Cancer Inst 2001,
93:678-683.
3. Ren S, Liu S, Howell P Jr: The Impact of Genomics in Understanding
Human Melanoma Progression and Metastasis. Cancer Control 2008,
15:202-215.
4. Alban A, David SO, Bjorkesten L: A novel experimental design for
comparative two-dimensional gel analysis: two-dimensional difference
gel electrophoresis incorporating a pooled internal standard. Proteomics
2003, 3:36-44.
5. Fidler IJ: The relationship of embolie homogeneity, number, size and
viability to the incidence of experimental metastasis. Eur J Cancer 1973,
9:223-227.
6. Sun B, Zhang D, Zhang S: Hypoxia influences vasculogenic mimicry
channel formation and tumor invasion-related protein expression in
melanoma. Cancer Lett 2007, 249:188-197.
7. Zhang X, Guo Y, Song Y: Proteomic analysis of individual variation in
normal livers of human beings using difference gel electrophoresis.
Proteomics 2006, 6:5260-5268.
8. Ryu B, Kim DS, DeLuca AM: Comprehensive expression profiling of tumor
cell lines identifies molecular signatures of melanoma progression. PLoS
One 2007, 4(2):Le594.
9. Riker AI, Enkemann SA, Fodstad O: The gene expression profiles of
primary and metastatic melanoma yields a transition point of tumor
progression and metastasis. BMC Med Genomics 2008, 28:1-13.
10. Nambiar S, Mirmohammadsadegh A, Doroudi R: Signaling networks in
cutaneous melanoma metastasis identified by complementary DNA
microarrays. Arch Dermatol 2005, 141:165-173.
11. Varambally S, Yu J, Laxman B, Rhodes DR: Integrative genomic and
proteomic analysis of prostate cancer reveals signatures of metastatic
progression. Cancer Cell 2005, 8:393-406.
12. Rondepierre F, Bouchon B, Papon J: Proteomic studies of B16 lines:
involvement of annexin A1 in melanoma dissemination. Biochim Biophys
Acta 2009, 1794:61-69.
13. Al-Ghoul M, Brück TB, Lauer-Fields JL: Comparative proteomic analysis of
matched primary and metastatic melanoma cell lines. J Proteome Res
2008, 7:4107-4018.
14. Zuidervaart W, Hensbergen PJ, Wong MC: Proteomic analysis of uveal
melanoma reveals novel potential markers involved in tumor
progression. Invest Ophthalmol Vis Sci 2006, 47:786-793.
15. Tonge R, Shaw J, Middleton B: Validation and development of
fluorescence two-dimensional differential gel electrophoresis proteomics
technology. Proteomics 2001, 1:377-396.
16. Taraboletti G, Belotti D, Giavazzi R: Enhancement of metastatic potential
of murine and human melanoma cells by laminin receptor peptide G:
attachment of cancer cells to subendothelial matrix as a pathway for
hematogenous metastasis. J Natl Cancer Inst 1993, 85:235-240.
17. Elshaw SR, Sisley K, Cross N: A comparison of ocular melanocyte and
uveal melanoma cell invasion and the implication of alpha1beta1,
alpha4beta1 and alpha6beta1 integrins. Br J Ophthalmol 2001, 85:732-738.
18. Lee AS: GRP78 induction in cancer: therapeutic and prognostic
implications. Cancer Res 2007, 67:3496-3499.
19. Lemaire R, Menguellet SA, Stauber J: Specific MALDI imaging and profiling
for biomarker hunting and validation: fragment of the 11S proteasome
activator complex, Reg alpha fragment, is a new potential ovary cancer
biomarker. J Proteome Res 2007, 6:4127-4134.
20. Takashima M, Kuramitsu Y, Yokoyama Y: Overexpression of alpha enolase
in hepatitis C virus-related hepatocellular carcinoma: Association with
tumor progression as determined by proteomic analysis. Proteomics
2005, 5:1686-1692.
21. Li C, Xiao Z, Chen Z: Proteome analysis of human lung squamous
carcinoma. Proteomics 2006, 6:547-558.
Li et al. Journal of Experimental & Clinical Cancer Research 2010, 29:109
http://www.jeccr.com/content/29/1/109
Page 8 of 922. Zieker D, Königsrainer I, Traub F: PGK1 a Potential Marker for Peritoneal
Dissemination in Gastric Cancer. Cell Physiol Biochem 2008, 21:429-436.
23. Payette MJ, Katz M, Grant-Kels JM: Melanoma prognostic factors found in
the dermatopathology report. Clinics in Dermatology 2009, 27:53-74.
24. Wei J, Xu G, Wu M: Overexpression of vimentin contributes to prostate
cancer invasion and metastasis via src regulation. Anticancer Res 2008,
28:327-334.
25. Zhou C, Nitschke AM, Xiong W: Proteomic analysis of tumor necrosis
factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-
mediated epithelial-mesenchymal transition phenotype. Breast Cancer Res
2008, 10:R105.
26. Chen YR, Juan HF, Huang HC: Quantitative proteomic and genomic
profiling reveals metastasis-related protein expression patterns in gastric
cancer cells. J Proteome Res 2006, 5:2727-2742.
27. Wang JW, Peng SY, Li JT: Identification of metastasis-associated proteins
involved in gallbladder carcinoma metastasis by proteomic analysis and
functional exploration of chloride intracellular channel 1. Cancer Lett
2009, 281:71-81.
28. Hendrix MJ, Seftor EA, Chu YW: Coexpression of vimentin and keratins by
human melanoma tumor cells: correlation with invasive and metastatic
potential. J Natl Cancer Inst 1992, 84:165-74.
29. Ben-Ze’ev A, Raz A: Relationship between the Organization and Synthesis
of Vimentin and the Metastatic capability of B16 melanoma Cells. Cancer
Res 1985, 45:2632-2641.
30. Gonzales M, Weksler B, Tsuruta D: Structure and function of a vimentin-
associated matrix adhesion in endothelial cells. Mol Biol Cell 2001,
12:85-100.
31. Hynes RO: Integrins: bidirectional, allosteric signaling machines. Cell 2002,
110:673-687.
32. Wu Y, Zhou BP: New insights of epithelial-mesenchymal transition in
cancer metastasis. Acta Biochim Biophys Sin (Shanghai) 2008, 40:643-50.
33. Dissanayake SK, Wade M, Johnson CE: The Wnt5A/protein kinase C
pathway mediates motility in melanoma cells via the inhibition of
metastasis suppressors and initiation of an epithelial to mesenchymal
transition. J Biol Chem 2007, 282:17259-17234.
34. Alonso SR, Tracey L, Ortiz P: A high-throughput study in melanoma
identifies epithelial-mesenchymal transition as a major determinant of
metastasis. Cancer Res 2007, 67:3450-3460.
doi:10.1186/1756-9966-29-109
Cite this article as: Li et al.: A novel function for vimentin: the potential
biomarker for predicting melanoma hematogenous metastasis. Journal
of Experimental & Clinical Cancer Research 2010 29:109.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Li et al. Journal of Experimental & Clinical Cancer Research 2010, 29:109
http://www.jeccr.com/content/29/1/109
Page 9 of 9